Introduction: The role of vitamin D in metabolism, bone-mineral regulation, and anti-oxidation effect has drawn researchers’ attention toward its exact role in hemodialysis.
Objectives: In this study, the effect of uric acid level reduction on serum 25-hydroxy vitamin D levels in hemodialysis patients was assessed.
Patients and Methods: This study is a triple-blind clinical trial conducted on 81 hemodialysis patients suffering from asymptomatic hyperuricemia. Serum uric acid levels were assessed at the start of the study. Then patients were divided randomly into two groups of intervention and control. The intervention group received 100 mg of allopurinol tablets daily for two months. The control group received placebo tablets for the same duration. At the end of the study, 25-hydroxyvitamin D and uric acid levels were assessed. Data were analyzed using SPSS software and chi-square, independent t test, Mann–Whitney U, and Spearman’s rank correlation tests.
Results: In our study, two groups of control and intervention were similar in terms of patients’ demographic and hemodialysis characteristics. After the intervention, compared to the control group, the serum uric acid levels were significantly lower in the intervention group, while the level of 25-hydroxyvitamin D showed no significant difference between the two groups.
Conclusion: In this study, no significant effect of uric acid lowering therapy with vitamin D elevation in hemodialysis patients was detected.
Trial Registration: The trial protocol was approved by the Iranian Registry of Clinical Trials (identifier: IRCT2015041721803N1; https:// en.irct.ir/trial/18996, ethical code#IR.SKUMS.1395.231).